Pacritinib

SAN DIEGO — Pacritinib may provide a “unique survival advantage” for patients with myelofibrosis also exhibiting moderate or severe thrombocythemia, according to data from the PERSIST-2 study, presented at ASH Annual Meeting and Exposition.

John O. Mascarenhas, MD, spoke with Healio about takeaways from a presentation examining ways to optimize the currently available JAK2 inhibitors for the treatment of myelofibrosis.

The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia.

In this video, Aaron T. Gerds, MD, MS, discusses data presented at ASH Annual Meeting and Exposition about the long-term treatment with pacritinib in patients with advanced myelofibrosis.

Aaron T. Gerds, MD, MS, speaks with Healio about the safety of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Aaron T. Gerds, MD, MS, speaks with Healio about the challenge dosing for ruxolitinib in patients with thrombocytopenia and the development of pacritinib as a Janus kinase inhibitor “specifically for patients with low platelet counts.”

Aaron T. Gerds, MD, MS, speaks with Healio about results from a retrospective analysis of data from the Persist-2 study presented at ASH Annual Meeting and Exposition.

The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer.